Bristol-Myers Cancer Drug’s Sales Stall as Merck Rival Gains
This article is for subscribers only.
Bristol-Myers Squibb Co. said that U.S. sales have stalled for Opdivo, the cancer drug that makes up the core of the company’s growth. The drug is facing stiff competition from a rival therapy from Merck & Co.